Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Alternative Names: Coformulation favezelimab/pembrolizumab - Merck Sharp & Dohme; Mavezelimab/pembrolizumab - Merck Sharp & Dohme; MK 4280A; MK-4820A; Pembrolizumab/favezelimab - Merck Sharp & Dohme

Latest Information Update: 29 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Colorectal cancer; Endometrial cancer; Hodgkin's disease; Malignant melanoma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 16 Dec 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in China (IV)
  • 16 Dec 2024 Discontinued - Phase-I/II for Bladder cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Netherlands (IV)
  • 16 Dec 2024 Discontinued - Phase-I/II for Hodgkin's disease (In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in South Korea (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top